Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market, By Type (IgG, IgA, and IgM), By Disease Indication (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CL

Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market, By Type (IgG, IgA, and IgM), By Disease Indication (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CLL), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Human immunoglobulin for intravenous injection (IVIG) has the capacity of proving passive immunity and anti-inflammatory, immunomodulatory effect which results in better treatment and prognosis of severe infections such as COVID-19. The IgG antibodies extracted from recovered patients of COVID- 19 are expected to boost the immune response in newly infected patients, leading to a reduction in the treatment duration. Hence, the combination of the immune IgG antibodies as human immunoglobulin for intravenous injection (IVIG) with antiviral drugs can offer short-term and medium-term solutions against COVID-19. Hence, the COVID-19 outbreak is expected to increase demand for human immunoglobulin (pH4) for intravenous injection which is expected to boost the growth of human immunoglobulin (pH4) for intravenous injection (COVID-19) market.
Market Dynamics
The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to enhance their market presence is expected to propel the market growth during the forecast period. For instance, in January 2020, ADMA Biologics, Inc., a manufacturer and distributor of plasma-derived biologics, entered a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA’s Immune Globulin (IG) manufacturing process. Under this agreement ADMA Biologics, Inc. will maximize the revenue per liter of plasma fractionated in its plant by selling the fractioned plasma to a third party to develop their own therapeutic products under their own licensed manufacturing processes.
Key features of the study:
This report provides in-depth analysis of the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, disease indication up-gradation, market expansion, and marketing tactics
The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market
Detailed Segmentation:
Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Type:
IgG
IgA
IgM
Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Disease Indication:
COVID-19
Primary Immunodeficiency Disease
Immune-mediated Thrombocytopenia
Kawasaki Disease
B Chronic lymphocytic Leukemia(B-CLL)
Others
Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Region:
North America
By Type
IgG
IgA
IgM
By Disease Indication:
COVID-19
Primary Immunodeficiency Disease
Immune-mediated Thrombocytopenia
Kawasaki Disease
B Chronic lymphocytic Leukemia(B-CLL)
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Type
IgG
IgA
IgM
By Disease Indication:
COVID-19
Primary Immunodeficiency Disease
Immune-mediated Thrombocytopenia
Kawasaki Disease
B Chronic lymphocytic Leukemia(B-CLL)
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type
IgG
IgA
IgM
By Disease Indication:
COVID-19
Primary Immunodeficiency Disease
Immune-mediated Thrombocytopenia
Kawasaki Disease
B Chronic lymphocytic Leukemia(B-CLL)
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type
IgG
IgA
IgM
By Disease Indication:
COVID-19
Primary Immunodeficiency Disease
Immune-mediated Thrombocytopenia
Kawasaki Disease
B Chronic lymphocytic Leukemia(B-CLL)
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type
IgG
IgA
IgM
By Disease Indication:
COVID-19
Primary Immunodeficiency Disease
Immune-mediated Thrombocytopenia
Kawasaki Disease
B Chronic lymphocytic Leukemia(B-CLL)
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Type
IgG
IgA
IgM
By Disease Indication:
COVID-19
Primary Immunodeficiency Disease
Immune-mediated Thrombocytopenia
Kawasaki Disease
B Chronic lymphocytic Leukemia(B-CLL)
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Takeda Pharmaceutical Company Limited*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Baxter International Inc.
CSL Behring
Bayer AG
Grifols, S.A.
Octapharma AG
Shanghai RAAS Blood Products Co., Ltd.
Hualan Biological Engineering Inc.
China Biologic Products, Inc.
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Boya Bio-Pharmaceutical Group Co., Ltd.
ADMA Biologics, Inc.
Sinopharm Group Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.